PaperPaper Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study External Link Read MorePaper XPO1 (CRM1) inhibition represses STAT3 activation to drive a surviving-dependent oncogenic switch in triple negative breast cancer. External Link Read MorePaper Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias External Link Read MorePaper Genome wide studies in Multiple Myeloma identify XPO1/CRM-1 as a critical target validated using the selective nuclear export inhibitor KPT-276. External Link Read MorePaper CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant melanoma External Link Read MorePaper CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications External Link Read MorePaper Prognostic impact and targeting of CRM1 in acute myeloid leukemia External Link Read MorePaper KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia External Link Read MorePaper Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells External Link Read MorePaper Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma External Link Read More Previous 1 … 4 5 6 7 Next